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Recent preclinical work investigating the role of progenitor cell therapies for central nervous system (CNS) injuries has shown
potentialneuroprotectioninthesettingoftraumaticbraininjury(TBI),spinalcordinjury(SCI),andischemicstroke.Mechanisms
currently under investigation include engraftment and transdiﬀerentiation, modulation of the locoregional inﬂammatory milieu,
andmodulationofthesystemicimmunologic/inﬂammatoryresponse.Whiletheexactmechanismofactionremainscontroversial,
thegrowingamountofpreclinicaldatademonstratingthepotentialbeneﬁtassociatedwithprogenitorcelltherapyforneurological
injury warrants the development of well-controlled clinical trials to investigate therapeutic safety and eﬃcacy. In this paper, we
review the currently active or recently completed clinical trials investigating the safety and potential eﬃcacy of bone marrow-
derived progenitor cell therapies for the treatment of TBI, SCI, and ischemic stroke. Our review of the literature shows that while
the preliminary clinical trials reviewed in this paper oﬀer novel data supporting the potential eﬃcacy of stem/progenitor cell
therapies for CNS injury, a great deal of additional work is needed to ensure the safety, eﬃcacy, and mechanisms of progenitor cell
therapy prior to widespread clinical trials.
1.Introduction
Central nervous system (CNS) insults including ischemic
stroke, traumatic brain injury (TBI), and traumatic spinal
cord injury (SCI) represent a major burden to the health-
care system worldwide. Approximately 5 million people
are burdened by the long-term physical, cognitive, and
psychosocial deﬁcits associated with TBI in the United States
with 40% of patients reporting unmet needs 1 year post
injury [1]. Furthermore, a recent analysis of stroke patients
hasshownalifelonghealthburdenof9.5qualityadjustedlife
years associated with an initial cerebrovascular accident [2].
Overall, the economic impact of traumatic and acute CNS
insults reaches several billion dollars in the United States
alone [3, 4].
Preliminary research is currently underway to evaluate
the potential eﬃcacy of adult tissue progenitor (stem) cell
therapies for the treatment of CNS injury. Adult tissue pro-
genitorcellsarelocatedinselectmicroenvironments(niches)
which protect against overproliferation and depletion as
well as regulate progenitor cell involvement in resident
tissue repair and regeneration [5]. By deﬁnition, progenitor
cells are multipotent with the capacity of self-renewal [6]
making them prime candidates for the development of2 Stem Cells International
novel therapies. Our paper will focus on progenitor cell
populations derived from the bone marrow and umbilical
cord blood niches including mesenchymal stromal cells
(MSCs) and hematopoietic stem cells (HSCs). There are
currently no clinical trials utilizing embryonic stem cells or
induced pluripotent stem cells for TBI, stroke, or SCI.
2. Therapeutic Mechanism
Recent preclinical work investigating bone marrow derived-
progenitor cell therapies for CNS injury has shown potential
neuroprotection after TBI [7], ischemic stroke [8], and SCI
[9]. While initial research indicated engraftment and trans-
diﬀerentiation into neural cells could explain the observed
beneﬁt [10], the exact mechanism remains controversial.
Potential mechanisms currently under investigation include
engraftment and transdiﬀerentiation, modulation of the
locoregional inﬂammatory milieu, and modulation of the
systemic immunologic/inﬂammatory response.
2.1. Engraftment and Transdiﬀerentiation. Preliminary
research completed in the Chopp laboratory showed both
motor and cognitive improvement after the intravenous
injection of MSCs in a rodent TBI model. The injected
MSCs were found to migrate towards the site of injury,
engraft, and display neuronal (neuronal nuclei (NeuN)) and
astrocytic (glial ﬁbrillary acidic protein (GFAP)) markers
[11]. Hayase et al. have successfully induced MSCs to form
neural spheres in vitro with subsequent implantation into
rodent cortex after focal ischemic injury. The implanted
progenitor cells were found to display neural cell markers
and engraft up to 100 days after injury with associated
behavioral recovery [12]. The Ha laboratory implanted
umbilical cord blood-derived progenitor cells (HUCBCs)
into the injury site after spinal cord contusion in a rodent
model. The HUCBCs were found to engraft at the site of
injury and diﬀerentiate into neural cells as evident by GFAP
and microtubule-associated protein 2 (MAP2) staining.
Locomotor testing showed functional improvement for all
time points tested up to 8 weeks after SCI [13].
Despite the promising research showing engraftment
and transdiﬀerentiation of transplanted progenitor cells into
neural cells, the importance of engraftment and frequency of
transdiﬀerentiation remain extremely controversial [14, 15].
The implantation of HSCs into murine striatum [16]a n d
injury zone of spinal cord contusion [17] showed diﬀeren-
tiation into macrophages or microglia but failure to transd-
iﬀerentiate into neurons. Furthermore, the implantation of
MSCs into demyelinated spinal cord showed migration into
normal tissue and failure of transdiﬀerentiation associated
with collagen deposition and further axonal injury [18].
Whilethedirectimplantationofprogenitorcellswithtransd-
iﬀerentiation into neurons could aﬀord neuroprotection, the
low frequency of engraftment and diﬀerentiation may limit
this pathway as a mechanism for functional recovery.
2.2. Modulation of the Locoregional Inﬂammatory Response.
Progenitor cell migration towards the site of injury and
interaction with resident microglia could modulate the
locoregional inﬂammatory response leading to enhanced
neuroprotection. Harting et al. investigated the local intrac-
erebral inﬂammatory response after TBI by completing a
series of rodent cortical injuries followed by the harvest
of intracerebral ﬂuid from 6 to 72 hours after injury.
Multiplex cytokine analysis of the intracerebral ﬂuid showed
an increase in the proinﬂammatory cytokines IL-1α,I L - 1 β,
IL-6, and TNFα in the direct injury and penumbral areas
[19]. The observed increase in cytokine production oﬀers an
attractive target for novel cell therapies.
Coculture of human MSCs with immunologic cells
(dendritic cells and T cells) was associated with an increase
in the anti-inﬂammatory cytokines interleukin 4 (IL-4)
and interleukin 10 (IL-10) in accordance with a decrease
in the proinﬂammatory cytokine interferon gamma (IFN-
γ). An increase in the proportion of T regulatory cells
with MSC coculture was also observed [20]. Walker et
al. directly implanted MSCs into the cortex of rodents
after TBI and found an increase of interleukin 6 (IL-6)
in brain tissue supernatants. Subsequently, a series of in
vitro MSC and neuronal stem cell (NSC) cocultures showed
activation of the NSC NFκB pathway leading to a decrease
in apoptosis [21]. The Wen laboratory has shown increased
intracerebral IL-10 with decreased tumor necrosis α (TNFα)
leading to improved cognitive performance after the direct
implantation of MSCs using a rodent ischemic stroke model
[22]. These promising preliminary studies have shown that
modulation of the locoregional postinjury proinﬂammatory
environment could aﬀord neuroprotection.
2.3. Modulation of the Systemic Immunologic Response.
Recent work completed in the Pennypacker laboratory has
shown that the adrenergic output associated with rodent
ischemic stroke leads to the release of immunologic cells (T
cells) from the spleen into the systemic circulation causing a
reduction in splenic mass and an increase in cavity volume.
Treatment with the panadrenergic blocker carvediol pre-
vented the loss of splenic mass and decreased cavity volume
[23]. Using a similar model, Verdrame et al. have shown that
the immunologic cells released into the systemic circulation
are mainly composed of cytotoxic CD8+ T cells potentially
exacerbating neurological injury observed with ischemic
stroke. The intravenous injection of HUCBCs in the stroke
model also prevented the loss of splenic mass and decreased
cavity size likely via a reduction in CD8+ cell release [24].
Additional research investigating the potential inter-
action between transplanted progenitor cells and lung
immunologic cells is currently underway. Using a murine
sepsis model, the Mezey laboratory has shown that the
intravenous injection of MSCs is associated with decreased
mortality and improved organ function. The observed bene-
ﬁt was derived from interactions between the injected MSCs
andlungmacrophagesleadingtoincreasedIL-10production
via a prostaglandin E2-dependent mechanism. Furthermore,
the beneﬁcial eﬀect was eliminated by the administration
of antibodies to either IL-10 or the IL-10 receptor thereby
conﬁrming the importance of anti inﬂammatory cytokine
production in therapeutic eﬃcacy [25].Stem Cells International 3
There is limited data on the interaction of implanted
adult progenitor cells with other organ systems in the setting
of neurologic injury. Distribution studies have demonstrated
localization of implanted cells to liver and kidney in addition
to the more commonly described spleen and lung after
intravenous or intra-arterial administration [26–29]. To our
knowledge,thereisnopublisheddataontheliverand/orkid-
neyactingaspotentialbioreactorsforcytokine/growthfactor
secretion after progenitor cell therapy for neurologic injury.
Preliminary preclinical work investigating the potential
role of progenitor cell therapeutics for CNS injury has
shown promise. The mechanism of the observed beneﬁt
remains controversial; however, more recent data questions
the frequency and clinical signiﬁcance of transdiﬀerentiation
as well as the volume of cells reaching the injury site due to
a signiﬁcant pulmonary ﬁrst-pass eﬀect [30]. We believe that
a more plausible explanation is that for some types of cell-
based therapies, the transplanted cells are interacting with
distant organ systems leading to alteration in the systemic
inﬂammatory/immunologic response. Progenitor cells could
interact with resident lung macrophages and splenic T
cells leading to an increase in anti inﬂammatory cytokine
production. The observed increase in systemic anti inﬂam-
matorycytokineconcentrationsmayaﬀecttheresidentbrain
microglia accounting for the observed therapeutic beneﬁt.
3.ClinicalTrials
The growing amount of preclinical data showing the
potential beneﬁt associated with progenitor cell therapy
warrants the development of well-controlled clinical trials
to investigate therapeutic safety and eﬃcacy for central
nervous system insults such as ischemic stroke, SCI, and TBI.
Below we review the preliminary clinical trials investigating
progenitor cell therapy for CNS insults completed to date.
3.1. Ischemic Stroke. Stroke is a leading cause of long-
term disability in the United States [31]. Intravenous tissue
plasminogen activator (tPA) is the only proven treatment
for acute ischemic stroke within the ﬁrst three hours of
symptom onset [32]. Cell-based therapies have emerged as
a novel and highly promising investigational approach to
enhance recovery after stroke in animal models [33–37]. The
encouragingpreliminaryresultshaveledseveralinvestigators
to launch clinical trials evaluating the safety of cell-based
therapies in stroke patients. The safety, feasibility, ideal cell
type, optimal dosage, and most favorable delivery method of
cells are currently unknown.
Savitz et al. are currently conducting a prospec-
tive, Phase 1 trial (http://www.clinicaltrials.gov/ Identiﬁer:
NCT00859014) evaluating the safety of bone marrow aspi-
ration and infusion of bone marrow mononuclear cells
(BMMCs) in adults within 24–72 hours of ischemic stroke.
Primary outcome measures include a series of short- and
long-term safety assessments with a secondary evaluation
of neurological function as measured up to 90 days after
injury. Autologous BMMCs are administered via peripheral
intravenous injection followed by serial measurements of
hemodynamic variables to assess immediate postinfusion
safety. Selected inclusion criteria are middle cerebral artery
(MCA) territory infarct, age between 18 and 80 years, and
National Institutes of Health Stroke Scale (NIHSS) between
6 and 20.
Lin et al. (China University Hospital, Taichung, Taiwan)
have recently completed a Phase 1 clinical trial ensuring
the safety of the direct intracerebral transplantation of
CD34+ progenitor cells in stroke patients. The CD34+
progenitor cells were obtained from peripheral blood of
patients with MCA strokes occurring within the past 6
to 60 months. Currently, a Phase 2 trial is recruiting
patients to determine the potential eﬃcacy of CD34+
cell implantation (http://www.clinicaltrials.gov/ Identiﬁer:
NCT00950521). The treatment group is to receive conven-
tional rehabilitation as well as the direct implantation of
CD34+ progenitor cells with the control group receiving
conventional rehabilitation alone. The primary outcome
is NIHSS scores collected serially for up to 12 months.
Inclusion criteria are patients between 35 and 70 years old
and an NIHSS between 9 and 20. The investigators plan to
enroll 60 patients and is currently underway.
Hern´ andez et al. (Hospital Universitario Central de
Asturias, Asturias, Spain) are currently enrolling patients
for a Phase 2 trial investigating the safety and eﬃcacy of
the intra arterial delivery of autologous CD34+ progenitor
cells into the MCA after ischemic stroke. Cellular harvest
and injection occurs between 5 and 9 days after the onset
of stroke symptoms. Patient hemodynamics and neurologic
status are monitored in the acute setting with follow up
exams up to 6 months after treatment. Adverse events
are classiﬁed as any worsening of the neurologic exam.
Therapeutic eﬃcacy is determined via serial physical, labora-
tory, and radiographic exams. Selected inclusion criteria are
symptoms and signs of clinically deﬁnite MCA acute stroke
(http://www.clinicaltrials.gov/ Identiﬁer: NCT00761982).
Andr´ e et al. (Federal University of Rio de Janeiro, Rio
de Janeiro, Brazil) are conducting a Phase 1 clinical trial
investigating the intravenous and intra arterial injection
of the autologous bone marrow-derived mononuclear cell
fraction within 90 days of MCA stroke. A cell dosage of up
to 500 × 106 mononuclear cells will be used. Patients will be
monitored with serial physical and radiographic exams up to
4 months after treatment. Adverse events will be recorded as
any worsening in neurologic exam. Transcranial doppler will
be used during intra arterial injection to ensure adequate
blood ﬂow in the middle cerebral artery. Improvement in
neurologic deﬁcits and neuroimaging will be recorded as
secondary outcome measures during the study time period.
Patients who are between 18 and 75 years old with an
MCA infarct documented on imaging, and NIHSS scores
between 4 and 20 are eligible (http://www.clinicaltrials.gov/
Identiﬁer: NCT00473057).
Habib et al. (Imperial College London, London, Eng-
land) are completing an additional Phase 1 trial investigating
the safety of intra arterial injection of the autologous bone
marrow CD34+ progenitor cell population into the MCA
of patients with acute anterior circulation strokes. Safety is
to be assessed by physical exam and laboratory parameters.4 Stem Cells International
Table 1: Listing of location and details of current clinical trials being completed to investigate the potential role of bone marrow-derived
progenitor cell therapeutics for the treatment of ischemic stroke.
Location of Study Study Design Deliver
Route
Sample
Size Cell Type Inclusion Criteria Outcomes Time
Window
United States
(The University of
Texas in Houston)
Single arm IV 10 Autologous
BMMCs
-M C As t r o k e
- 18–80yo
-N I H S S6t o2 0
Safety and
feasibility
24 to
72hrs
Taiwan
(The China Medical
University Hospital)
Randomized
(cell infusion
versus
conventional
treatment)
IC 30
Autologous
peripheral
blood CD34+
cells
- Stable deﬁcits hemiplegia
- 35–70yo
-N I H S S9t o2 0
Safety and
eﬃcacy
6m o n t h s
to 5 years
Spain
(Hospital
Universitario Central
de Asturias)
Single arm IA 20
Autologous
CD34+ bone
marrow cells
-M C As t r o k e
- 18–80yo
-N I H S S≥ 8
Safety 5t o9
days
France
(University Hospital
of Grenoble)
Randomized
(Control
versus 2
treatment
groups)
IV 30
Autologous
bone marrow
derived
progenitor
cells
- Carotid territory stroke
- 18–65yo
-N I H S S> 2
Feasibility
and
tolerability
6w e e k s
United Kingdom
(Imperial College
London)
Single arm IA 10
Autologous
CD34+ bone
marrow cells
-M C As t r o k e
- 30–80yo
- Severe stroke conforming to the
TACS phenotype (weakness,
homonymous hemianopia and a
focal cognitive deﬁcit
Safety and
tolerability 7d a y s
Brazil
(Federal University of
Rio de Janeiro)
2 arms (non
randomized:
10 IA/5IV)
IV/IA 15 Autologous
BMMCs
-M C As t r o k e
- 18–75yo
-N I H S S4t o2 0
Safety 3hrsto
90 days
IV: intravenous; IA: intra-arterial; IC: intracerebral; BMMC: bone marrow mononuclear cells; MCA: middle cerebral artery; NIHSS: National Institutes of
Health Stroke Scale; TACS: total anterior circulation stroke.
Improvement in clinical function as assessed by the Modiﬁed
Rankin Score and NIHSS is secondary outcome that will
be evaluated. Selected inclusion criteria include a clinically
deﬁnite acute stroke with known onset time, ability to start
treatment within 7 days of onset, and patients between
30 and 80 years old. Data collection for the trial is set
to be completed in May 2010 (http://www.clinicaltrial.gov/
Identiﬁer: NCT00535197).
Preliminary clinical trials investigating the role of cell
therapeutics for ischemic stroke have been limited to date
and powered only to evaluate safety (Table 1). The majority
of these studies are restricting enrollment to patients with
MCAinfarctsterritoryanddonotassesstheroleofthesecells
in other areas of the brain. No optimal method of delivery
has been established, and it is unclear whether intravenous,
intra-arterial, or other approaches may be safer and lead to
better outcomes. Additionally, the studies employ diﬀerent
outcome measures limiting the ability to compare results
among trials. While these preliminary studies have yielded
some data to support the safety of cellular transplantation,
additional trials need to be completed prior to controlled
multicenter trials. A recent consensus conference (STAIR)
was convened to discuss the future of clinical trials in stroke.
Theconsensushighlightedtheneedforwell-designedclinical
trials with cell therapy being an excellent candidate [38].
3.2.TraumaticBrainInjury. AsearchoftheClinicaltrials.gov
database identiﬁed 279 ongoing or recently completed clini-
caltrialsforpatientswithTBI(searchperformed3/31/2010).
The treatments were focused on both acute therapy, as well
as ongoing or chronic therapy, and included (but were not
limited to) medications (i.e., amantadine, carbamazepine,
oxycyte, or erythropoietin), hyperbaric oxygen, hypother-
mia, educational interventions, and physical rehabilitation.
Using the search terms “stem cell” and “brain” identiﬁed
nearly 300 studies, including studies evaluating the use
of adult stem cells (administered via various routes, in
various numbers, and using various cell types) to treat
hypoxic/ischemic encephalopathy, cerebral palsy, multiple
sclerosis, amyotrophic lateral sclerosis, neuronal ceroid lipo-
fuscinosis, Parkinson’s disease, and others.
A single Phase I study using bone marrow-derived
mononuclear cells in children after isolated TBI has recently
been completed. In this study, 10 children age 5–14 years
with a Glasgow coma scale score of 5–8 were treated with 6
× 106 bone marrow-derived mononuclear cells per kg body
weight delivered intravenously within 48 hours of an isolated
TBI. To determine the safety of administration, systemic
and cerebral hemodynamics, laboratory parameters, chest
radiographs, and serial clinical assessments were monitored.
Additionally, serial cerebral magnetic resonance imaging,Stem Cells International 5
neuropsychologic evaluation, and functional outcome mea-
sures were obtained as preliminary measures of eﬃcacy.
There were no identiﬁable adverse events with close
monitoringoftheneurologic,pulmonary,renal,hepatic,and
hematologic systems. Functional and neuropsychological
testing, including the Glasgow Outcome Scale, the Pediatric
Injury Functional Outcome Scale, and the Wechsler Abbre-
viated Scale of Intelligence, revealed recovery consistent with
(or improved from) expected baselines. Magnetic resonance
imaging volumetric data revealed no signiﬁcant change in
grey matter, white matter, intracranial volume, or CSF space
at 1 and 6 months as measured relative to expected norms
[39].
This study should open the door for translation of cell
therapies, particularly among patients with neurologic dis-
easesandamongpediatricpatients.Giventheapparentsafety
of this study, the development of larger, multicenter studies
to further assess dosing and eﬃcacy of autologous cell ther-
apyforTBIisunderway.Additionally,similar(moredispens-
able) progenitor cell populations, such as cord blood cells,
ma ybesafeandeﬃcaciousaswellandwarrantfurtherstudy .
3.3. Spinal Cord Injury
3.3.1. Human Trials Using Autologous BMMC Delivered by
Intravenous or Intra-Arterial Infusion. A trial comparing
autologous BMMC intravenous transplantation plus physi-
cal therapy to physical therapy only in patients with chronic
SCI has been reported from Al-Azhar University Military
Medical Academy in Cairo, Egypt. No outcomes data has
been published on this trial.
Sykov´ a et al. treated two groups of patients with
autologous BMMC via either intravenous infusion or intra-
arterial infusion through the vertebral artery. In the ﬁrst
group (subacute group), cell therapy was delivered between
10 and 33 days following SCI. The second group (chronic
group) was treated between 2 and 18 months after SCI. Of
the eight subacute patients, four were treated intravenously
and four via an intra-arterial route. Two of the chronic
patients were treated intra-arterially and the remaining ten
patients were treated intravenously. Patients were evaluated
3, 6, and 12 months post BMMC treatment. All four of the
subacute patients treated via the intra-arterial route and one
of the four treated intravenously experienced improvement
in the American Spinal Injury Association (ASIA) score. One
of two chronic patients treated via an intra-arterial route
experienced an improvement in ASIA score, but none of
the remaining 10 chronic patients treated with intravenous
administration of BMMCs improved [40].
Cristante et al. treated 39 patients with chronic SCI
using peripheral stem cell mobilization (granulocyte
monocyte colony stimulating factor (GM-CSF) treatment)
and subsequent collection by apheresis. The patients all had
complete SCI of two or more years duration. At least 2.5 ×
106 CD34+ cells per kg body weight were collected. Cells
were delivered intra-arterially into the anterior spinal artery
at or near the level of their SCI. Patients were followed with
serial somatosensory-evoked potential (SSEP) testing over
30 months. Overall 66.7% of patients experienced improved
latency on SSEP evaluation. No diﬀerence in response rates
was identiﬁed between paraplegic or quadriplegic patients
[41].
Our group has recently obtained an investigational new
drug (IND) application to treat chronic (greater than 6
months post injury) pediatric SCI with autologous BMMC
via intravenous infusion. Patients will receive pre- and
serial posttreatment neurologic examinations, ASIA Scale
ratings, SSEP testing, cystometrogram (CMG) testing, and
spinal magnetic resonance imaging with diﬀusion tensor
tractography. We expect to begin enrolling patients by late
summer 2010.
3.3.2. Human Trials Using Autologous BMMC Delivered by
Lumbar Puncture. Callera et al. treated a total of 10 patients
with established SCI. Patients were pretreated with GM-
CSF for 5 days and then treated with 100 × 106 autologous
BMMC by lumbar puncture (LP). Patients underwent repeat
LP 7 days posttreatment and the repeat LPs were reported to
be normal. No mention of functional outcome was reported
[42]. The same group of investigators treated 16 cases of
chronic SCI with either autologous bone marrow-derived
CD45+ cells labeled with iron nanoparticles (10 patients)
or iron nanoparticles only (6 patients) by lumbar puncture.
Serial magnetic resonance imaging scans performed follow-
ing treatment demonstrated cell migration to the edges of
the SCI in 5 of the cell-treated patients but none of the nano-
particles only treated patients [43].
3.3.3. Human Trials Using BMMC Delivered by Direct Injec-
tion or Surgical Implantation into the Injured Spinal Cord.
Deda et al. treated 9 patients with complete SCI (ASIA Grade
A) using a processed autologous bone marrow preparation
(cells harvested in Turkey, shipped to Ann Arbor, Michigan
for processing, and returned to Turkey for cell infusion).
Cells were delivered by intravenous infusion, direct injection
into the spinal cord above and below the injury site, and by a
cell-infused matrix implanted surgically into the injury site.
The authors reported improvement to ASIA Grade B of C in
treated patients, improved SSEP latencies in treated patients
and no adverse events [44].
Yoon et al. treated a total of 35 patients with SCI using
direct injection of BMMCs into six sites surrounding the
spinal cord injury. Patients were divided into acute (treated
within 2 weeks of injury), subacute (treated between 2 and 8
weeksfrominjury),andchronic(treatedgreaterthan8weeks
from injury) treatment groups. All treated patients also
received GM-CSF treatment for 5 months after treatment.
A control group of 13 patients who underwent surgery
without BMMC or GM-CSF treatment was included in the
study. Neurologic improvement (ASIA A to ASIA B or C)
was reported in roughly 30% of the acute and subacute
treatment groups, but not in in the chronic treatment
control groups. Neurologic improvements were greater in
patients with the greatest leukocytosis following GM-CSF
treatment. Neuropathic pain occurred in a third of the
subacute and chronically treated patients but in only one of
sixteen acutely treated patients. One control group patient
developed neuropathic pain [45].6 Stem Cells International
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(a)
(b)
Figure 1: (a) Brain MRI demonstrating a lesion (arrow) based on
the tentorium next to the brain stem (BS). (b) Spinal-lumbar MRI
(T2) showing an intradural lesion (arrow) at the level of the L4
v e r t e b r a .R e p r o d u c e dw i t hp e r m i s s i o n .
3.3.4. Human Trials Using Embryonically Derived Stem Cell
Products. Considerable regulatory caution has been exer-
cised when human trials using embryonically or fetally
derived stem cell products are proposed. Although these
more immature cell types have the theoretical advantage
of pluripotency, they have also been associated with tumor
formation. A case report from Israel describing the devel-
opment of multifocal CNS glioneuronal tumors following
treatment of a child with ataxia telangiectasia using fetal
neural stem cells (obtained from multiple human fetuses)
has caused researchers and regulators to move cautiously in
thisarea.Thetumorswereshowntohavedevelopedfromthe
transplanted fetal tissue (Figure 1)[ 46].
GeronCorporation (MenloPark,Calif, USA)hasstarted
a United States Food and Drug Administration (FDA)
approved trial using embryonically derived oligodendroglial
precursor cells (identical to those used by Kierstadt) to
replace myelin-forming cells within injured spinal cords.
The cell preparations are injected directly into the spinal
cordsatthelesionsite.Thetreatmentpopulationisrestricted
to adults with complete thoracic (T3–T9) level SCI. Patients
must undergo treatment within 7 to14 days following injury.
Preclinical data showing that SCI animals treated with
Geron’s cell line developed cysts at the level of treatment
caused the FDA to put a hold on the clinical trial. Geron
and the FDA have reached an agreement to allow the trail
to move forward if subsequent preclinical studies provide
satisfactory outcome.
4. Conclusions
Prior to large, multicenter clinical trials investigating the
potential eﬃcacy of progenitor cell therapies for CNS insults,
a number of issues need to be addressed. Further research
intooptimalcelldosing,celldeliverymethod,andtechniques
for in vivo cell tracking need to be completed to ensure
the safety of potential trials while aﬀording them the best
possible chance at success. Additional preclinical work to
more clearly delineate the progenitor cell mechanism of
action would also aid in the planning of quality-controlled
clinical studies. Overall, while the very preliminary clinical
trials reviewed in this paper oﬀer novel data supporting the
potential eﬃcacy of cell therapeutics for CNS injury, a great
deal of additional work is needed to ensure the safety and
eﬃcacyofprogenitorcelltherapypriortowidespreadclinical
trials.
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